High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, Brodersen L, Loken M, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN.
Hitzler J, et al.
Blood. 2021 Dec 9;138(23):2337-2346. doi: 10.1182/blood.2021012206.
Blood. 2021.
PMID: 34320162
Free PMC article.
Clinical Trial.